EHA 2026 | Insights into the real-world REVIVE study: venetoclax-based low-intensity therapy in AML

The REVIVE study is a multi-center, real-world, prospective observational study of 12 sites in Israel looking at patients treated in first line for AML with venetoclax-based low-intensity protocols, primarily venetoclax and azacitidine. So this was a non-interventional study, and we recruited 207 patients, and we looked initially at patient selection and various aspects of management and treatment and outcomes. And the primary results were already published last year in Blood Advances. And here in this meeting, we presented our data regarding various questions regarding management of care, primarily anti-infective prophylaxis, both antibacterial and antifungal, use of G-CSF, and setting of initiation of care, whether it’s inpatient or outpatient. And our findings are that we do not see any effect of anti-infective prophylaxis, at least in our environment, in terms of degrees of infection, toxicity of treatment, or efficacy of treatment. So I think what we can say from our data, which is in agreement with data from other centers, is that universal prophylactic antifungal and antibacterial treatment is probably not warranted, but should be individualized. And G-CSF, about 40% of patients received G-CSF in our study. And there was a numerical advantage in overall survival for these patients, but it didn’t reach statistical significance. And this has also been shown in other groups in post hoc analysis from the VIALE-A. So maybe if we get enough patients together, then we will be able to see something significant. But we do show a trend. And the final thing is outpatient treatment of AML patients. And what we see here is that if you carefully select your patients for the more fit patients with less burden of disease and a good social network, then this treatment is safe and feasible and we can get the same good outcomes with outpatient onboarding treatment that you get with inpatient boarding.